Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

GS030

25 Oct 2018

Ophthalmology Innovation Summit @ AAO, Chicago (IL)

27 Oct 2018 - 30 Oct 2018

American Academy of Ophthalmology, Chicago (IL)

26 April 2018

GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO

27 May 2018 - 30 May 2018

ISCAS 2018, Florence, Italy

16 May 2018 - 19 May 2018

21st Annual Meeting ASGCT, Chicago (IL), US

29 Apr 2018 - 03 May 2018

ARVO Annual Meeting, Honolulu, Hawaï, US

10 January 2018

GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa

16 October 2017

GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy

08 May 2017

GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO

31 January 2017

GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa

  • View previous 9 articles
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page